Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014 Prominent academics, leaders ... gather on December 3rd at Genetic Rx, a ... GeneticRx will take place at the Joseph B. ... will discuss the present and future of genetic ... and gene editing—as well as the treatment of ...
(Date:11/22/2014)... 22, 2014 The “Chiral Chromatography ... by Material (Metal, Glass, Plastic), by Application [GC, ... - Forecast to 2018” analyses and studies the ... North America, Europe, Asia, and Rest of the ... 15 figures spread through 135 pages and in-depth ...
(Date:11/21/2014)... November 21, 2014 , ...   Mariano Rodríguez es elegid vicepresidente senior ... KLOX está en marcha para comenzar de forma rápida ... heridas de reciente aprobación en Europa   , ... complace al anunciar los siguientes nombramientos: Todd ...
(Date:11/21/2014)... Author Matthew J. Pallamary’s second short ... Side” published as a tribute to his mentor ... Short Story” category of the 2014 USA Best ... of USA Book News, said this year’s contest yielded ... Simon & Schuster, Penguin, John Wiley & Sons, Houghton ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... 2011 The proposed rule for the Medicare Shared ... the Department of Health and Human Services on March ... sought by the health insurance lobby, a MedeAnalytics analysis ... "The proposed rule positively addresses many of the ...
... understanding the structure of proteins, polymers, minerals, and engineered ... of the journal Nature Materials . The discovery ... type of symmetry in the structure of materials, which ... or designing materials with desired properties. The research is ...
... WHITE PLAINS, N.Y., April 1, 2011 Once again, the ... Cancer shows a continued decline in diagnoses and deaths ... attributed primarily to preventive measures such as cessation of smoking ... http://photos.prnewswire.com/prnh/20110215/NY48642LOGO) But for many cancers, such as the ...
Cached Biology Technology:ACO Proposed Rule: Over 90 Percent of Commercial Payer RFI Suggestions Incorporated 2Search for advanced materials aided by discovery of hidden symmetries in nature 2Search for advanced materials aided by discovery of hidden symmetries in nature 3The Leukemia & Lymphoma Society: Accelerating Cures Must Be a Priority 2
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... A new study by Indiana University-Purdue University Indianapolis (IUPUI) ... fast food outlet increases weight in children and that ... as well as so called junk food, lowers weight. ... and urban planning compared children,s weights over time before ...
... from the University of Cadiz has confirmed that zinc, copper and ... of the Huelva estuary, and have studied how some of these ... cadmium and copper accumulate in the body tissues of sole and ... some metals in the waters of the Huelva estuary and those ...
... of scientists has discovered extensive similarities between a strain ... linked to opportunistic infections in hospital patients. The findings ... for a range of biotech applications. The genetic analysis ... Energy,s (DOE) Brookhaven National Laboratory, and will be published ...
Cached Biology News:IUPUI study finds living near fast food outlet not a weighty problem for kids 2Study shows transfer of heavy metals from water to fish in Huelva estuary 2Plant microbe shares features with drug-resistant pathogen 2Plant microbe shares features with drug-resistant pathogen 3
UGT1A7 (E-15)...
... nucleofection of optimized cell lines in combination ... nucleofection parameters. Nucleofector Kits are only functional ... cell lines can be transfected with this ... given in brackets in percent (Efficiency [%] ...
... Fluorescein 6-Fam, Hex, Tet Cy3, Cy5, ... Tamra Black Hole Quenchers Molecular Beacons* ... Tamra, Joe 3 Dabcyl Dabcyl*Licensed ... York Double labelled probes are purified either ...
... Protein Phosphatase ( l-PPase) ... phosphatase with activity towards ... tyrosine residues. It is ... of the ORF221 open ...
Biology Products: